Oncovista Innovative Therapies Inc
OTC:OVIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oncovista Innovative Therapies Inc
Total Current Assets
Oncovista Innovative Therapies Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oncovista Innovative Therapies Inc
OTC:OVIT
|
Total Current Assets
$61.3k
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Oncovista Innovative Therapies Inc
Glance View
OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company is headquartered in San Antonio, Texas. The company went IPO on 2006-01-23. The firm is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The firm's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The firm's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The firm's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.
See Also
What is Oncovista Innovative Therapies Inc's Total Current Assets?
Total Current Assets
61.3k
USD
Based on the financial report for Sep 30, 2015, Oncovista Innovative Therapies Inc's Total Current Assets amounts to 61.3k USD.
What is Oncovista Innovative Therapies Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-25%
Over the last year, the Total Current Assets growth was -49%. The average annual Total Current Assets growth rates for Oncovista Innovative Therapies Inc have been -59% over the past three years , -25% over the past five years .
